Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia

Annals of Oncology

Volumn 7, Issue SUPPL. 6, 1996, Pages

  O'Brien, S ^a   Kantarjian, H ^a   Keating, M J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

2 chlorodeoxyadenosine; 2 deoxycoformycin; CLL; Purine analogs; Waldenstr m's macroglobulinema

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE;

BONE MARROW SUPPRESSION; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFECTION; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; CLADRIBINE; CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PURINE NUCLEOSIDES; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 0030456923     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_6.S27     Document Type: Review

References (53)

1. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17: 3-17.
2. Kawasaki H, Carrera CJ, Piro LD et al. Relationship of deoxycytidine kinase and cytoplasmic 5′nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597-601.
3. Grever MR, Kopecky KJ, Coltman CA et al. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457-9.
4. Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
5. Hiddemann W, Rottmann R, Wörmann B et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine: Results of a clinical phase II study. Ann Hematol 1991; 63: 1-4.
6. DeRossi G, Mauro FR, Caruso R et al. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. Haematologica 1993; 78: 167-71.
7. Keating MJ, Kantarjian H, O'Brien S et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
8. O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-700.
9. Keating MJ, O'Brien S, Kantarjian H et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-84.
10. Puccio CA, Mittelman A, Lichtman SM et al. A loading dose/ continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 1562-9.
11. Kemena A, O'Brien S, Kantarjian H et al. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymph 1993; 10: 187-93.
12. Robertson LE, O'Brien S, Kantarjian H et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 1444-9.
13. Hiddemann W, Johnson S, Smith A et al. Fludarabine versus cyclophosphamide, adriamycin, prednisone (CAP) for the treatment of chronic lymphocytic leukemia. Blood 1993; 82 (Suppl 1): 199a (Abstr 781).
14. Binet JL, Chastang C, Chevret S et al. Comparison of fludarabine (FDB), CAP and CHOP in advanced previously untreated chronic lymphocytic leukemia (CLL): Preliminary results of a randomized clinical trial. Blood 1993; 82 (Suppl 1): 140a (Abstr 546).
15. Rai KR, Peterson B, Kolitz J et al. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomized Inter-group study. Blood 1995; 86 (Suppl 1): 607a (Abstr 2414).
16. McLaughlin P, Hagemeister FB, Swan F Jr et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12: 575-9.
17. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-4.
18. Hochster HS, Kim K, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28-32.
19. Leiby JM, Snider KM, Kraut EH et al. Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparision of response with deoxycytidine kinase activity. Cancer Res 1987; 47: 2719-22.
20. O'Brien S, Kantarjian H, Beran M et al. Fludarabine (FAMP) and cyclosporine (CTX) therapy in chronic lymphocytic leukemia (CLL). Presented at the Second Meeting of the European Haematology Association, May 29-June 1, 1996, Paris.
21. Gams RA, Bryan S, Dukart G et al. Mitoxantrone in malignant lymphoma. Invest New Drugs 1985; 3: 219-22.
22. Coltman CA, McDaniel TM, Balcerzak SP et al. Mitoxantrone hydrochloride (NSC-310739) in lymphoma: A Southwest Oncology Group study. Invest New Drugs 1983; 1: 65-70.
23. Silver RT, Case DC Jr, Wheeler RH et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9: 754-61.
24. Hansen MM, Hansen SW, Pedersen-Bjergaard J et al. Mitoxantrone in the treatment of chronic lymphocytic leukemia. Leuk Lymph 1992; 7: 305-7.
25. French Cooperative Group On Chronic Lymphocytic Leukaemia. Effectiveness of 'CHOP' regimen in advanced untreated chronic lymphocytic leukemia. Lancet 1986; 14: 1346-9.
26. Robertson LE, O'Brien S, Kantarjian H et al, Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9: 943-5.
27. Hochster H, Oken M, Bennett J et al. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL-ECOG 1491). Blood 1994; 84 (Suppl 1): 383a (Abstr 1517).
28. Smyth JF, Paine RM, Jackman AL et al. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 1980; 5: 93-101.
29. Smyth JF, Prentice HG, Proctor S et al. Deoxycoformycin in the treatment of leukemias and lymphomas. Ann NY Acad Sci 1985; 451: 123-8.
30. Grever MR, Siaw MFE, Jacob WF et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406-17.
31. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433-8.
32. Ho AD, Thaler J, Stryckmans P et al. Pentostatin in refractory chronic lymphocytic leukemia: A phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990; 82: 1416-20.
33. Piro L, Carrera CJ, Carson DA et al. Lasting remission in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-21.
34. Estey E, Kurzrock R, Kantarjian HM et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882-7.
35. Tallman MS, Hakimian D, Variakojis D et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-9.
36. Piro LD, Carrera CJ, Beutler E et al. 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069-73.
37. Saven A, Carrera CJ, Carson DA et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 1991; 5: 133-8.
38. Tallman MS, Hakimian D, Zanzig C et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983-8.
39. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocytic count. J Clin Oncol 1993; 11: 679-89.
40. Liliemark J, Pettersson B, Juliusson G. The relationship between plasma 2-chloro-2′-deoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent and continuous i.v. infusion in patients with chronic lymphocytic leukemia. Blood 1991; 78: 33a (Abstr 122).
41. Saven A, Lemon RH, Kosty M et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570-4.
42. Delannoy A, Martial P, Gala JL et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-5.
43. Mulligan SP, Eliadis P, Dale B et al. 2-Chlorodeoxyadenosine (2-CDA) in previously untreated chronic lymphocytic leukemia (CLL) - preliminary analysis from the Australian Leukemia Study Group Trial. Blood 1995; 86 (Suppl 1): 349a (Abstr 1385).
44. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 1992; 10: 1514-8.
45. Tefferi A, Witzig TE, Reid JM et al. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol 1994; 12: 569-74.
46. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056-61.
47. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328: 812.
48. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328(11): 812-3.
49. O'Brien S, Kantarjian H, Estey E et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine. N Engl J Med 1994; 330: 319-22.
50. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
51. Dimopoulos MA, O'Brien S, Kantarjian H et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 1993; 95: 49-52.
52. Dimopoulos MA, Kantarjian H, Estey E et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118: 195-8.
53. Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12: 2694-8.